Impurities & Reference Standards

Cat. No.

A25099

CAS No.

2748800-07-7

(2S,3R,4S)-ASX-173

(2S,3R,4S)-ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) with an IC50 of 0.113 μM and a Ki of 0.4 nM. This (2S,3R,4S)-enantiomer enhances the cytotoxic effects of L-asparaginase, resulting in disrupted nucleotide synthesis and promoting cell cycle arrest, apoptosis, and autophagy in leukemia cells. Additionally, (2S,3R,4S)-ASX-173 has demonstrated efficacy in slowing the growth of OCI-AML2 xenografts when used in combination with L-asparaginase, making it a valuable tool for research focused on acute lymphoblastic leukemia, acute myeloid leukemia, and colorectal cancer.

Cat. No.

A25104

CAS No.

634911-81-2

(Iso)-Z-VAD(OMe)-FMK

Synonyms: (Iso)-Z-Val-Ala-Asp(OMe)-FMK

(Iso)-Z-VAD(OMe)-FMK is a caspase and UCHL1 inhibitor, acting as an important tool for studying apoptosis and proteasomal degradation pathways. This isomer of Z-VAD(OMe)-FMK offers a unique structure that may influence its biological interactions and efficacy. Researchers can utilize this reagent in various applications including cell death assays and drug discovery efforts targeting apoptotic mechanisms.

Cat. No.

A29866

CAS No.

1214994-13-4

(S)-Indeloxazine benzenesulfonate

Synonyms: (S)-AS1069562; (S)-YM-08054 benzenesulfonate

(S)-Indeloxazine benzenesulfonate is the S-enantiomer of AS1069562, which acts primarily as a selective inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake with IC50 values of 0.35 μM and 3.3 μM, respectively. This compound exhibits curative-like analgesic effects and has potential applications in improving nerve function impairment through enhanced neurotrophic support. It is relevant in research focused on pain management and neurotherapeutics.

Cat. No.

A31200

CAS No.

10378-06-0

(6R)-FR054

(6R)-FR054 is a less active isomer of FR054, acting primarily as a modulator of biological pathways influenced by the parent compound. This reagent provides a valuable tool for comparative studies aimed at elucidating the mechanisms of action and specific contributions of the more active isomer. Researchers can utilize (6R)-FR054 in the development of experimental designs that require an understanding of molecular interactions and signaling processes.

Cat. No.

A33318

CAS No.

2328068-38-6

(S)-Lomedeucitinib

Synonyms: (S)-BMS-986322

(S)-Lomedeucitinib is the S-enantiomer of Lomedeucitinib and functions as a selective inhibitor of tyrosine protein kinase 2 (TYK2). This compound demonstrates significant potential in modulating immune responses and has applications in research related to autoimmune diseases and other TYK2-dependent pathways. Its structural properties and mechanism of action make it a valuable tool in the study of targeted therapies and signal transduction.

Cat. No.

A35431

CAS No.

2762081-31-0

(R)-SARM1-IN-5

(R)-SARM1-IN-5 is the (R)-enantiomer of a selective SARM1 inhibitor. This compound plays a crucial role in modulating axonal degeneration, making it applicable in research focused on neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Its inhibition of SARM1 offers valuable insights into potential therapeutic strategies for these conditions.

Cat. No.

A36290

CAS No.

3104612-73-6

KF-52 enantiomer

KF-52 enantiomer is a selective inhibitor of phosphofructokinase-1 (PFK1), an essential enzyme in glycolysis. By modulating PFK1 activity, this compound potentially affects glucose metabolism and energy production in cells. Its biological activity makes it a valuable tool for research into metabolic disorders and cancer biology, where altered glycolytic pathways are often implicated.

Cat. No.

A36843

CAS No.

2377238-62-3

(R)-AR-13503

Synonyms: (R)-AR-13324 M1 metabolite

(R)-AR-13503 is the (R)-enantiomer of AR-13503, primarily functioning as a ROCK kinase and PKC inhibitor. This compound exhibits significant anti-angiogenic properties and has demonstrated potential in supporting retinal health. Its unique biological activity makes (R)-AR-13503 a valuable tool for research focused on retinal diseases and associated therapeutic interventions.

Cat. No.

A37420

CAS No.

1028332-91-3

Retreversine

Retreversine is an inactive control compound specifically designed for use in conjunction with Reversine, an ATP-competitive Aurora kinase inhibitor. This reagent serves as a vital tool for validating experimental results in studies involving Aurora kinase pathways. Its unique structure allows researchers to effectively assess the specificity and effects of active inhibitors on cellular processes, making it essential for biochemical and pharmacological research applications.

Cat. No.

A37586

CAS No.

2241517-83-7

JG-258

JG-258 is an inactive negative control for Hsp70 inhibitors. It serves as a useful tool in experimental design, allowing researchers to discern specific effects attributed to active compounds. This reagent is particularly beneficial in studies focusing on the modulation of Hsp70 activity and in elucidating the biological roles of Hsp70 in various cellular processes.

Cat. No.

A37763

CAS No.

877969-69-2

VPC-80051 racemate

VPC-80051 racemate is a potent inhibitor of the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) splicing factor. This compound exhibits significant activity in modulating alternative splicing processes, making it a valuable tool for studying gene regulation and RNA processing. Research applications include investigations into the role of hnRNP A1 in various diseases and the development of potential therapeutic strategies targeting RNA splicing pathways.

Cat. No.

A37948

CAS No.

1903783-77-6

(+)-TK216 (d-TK216)

Synonyms: d-TK216

(+)-TK216 is the active enantiomer of TK216, serving as a potent inhibitor of the E26 transformation specific (ETS) transcription factors. This compound exhibits significant biological activity in modulating gene expression and has shown promise in cancer research due to its ability to disrupt ETS-related signaling pathways. It is a valuable reagent for investigating the role of ETS proteins in oncogenesis and other related cellular processes.

Cat. No.

A38021

CAS No.

1903783-78-7

(-)-TK216 (l-TK216)

(-)-TK216 is the enantiomer of TK216, a potent and orally bioavailable inhibitor of E26 transformation-specific (ETS) transcription factors. This compound exhibits significant anti-cancer activity, making it a valuable tool for research focused on gene regulation and oncogenic pathways. Its efficacy in targeting ETS-related mechanisms positions (-)-TK216 as a pertinent compound for investigative studies in cancer biology and therapeutic development.

Cat. No.

A38182

CAS No.

53330-02-2

S-(N-PhenethylthiocarbaMoyl)-L-cysteine

Synonyms: PEITC-Cys

S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys) functions primarily as a P450 inhibitor, exhibiting significant anticarcinogenic properties. This compound demonstrates notable antileukemic activity by inhibiting DNA synthesis in HL60 cells. PEITC-Cys is valuable for research applications focused on cancer biology and drug metabolism studies.

Cat. No.

A39091

CAS No.

1388151-90-3

(Rac)-Phox-I1

(Rac)-Phox-I1 is a racemic isomer of Phox-I1, functioning primarily as an inhibitor of p67phox. This compound effectively inhibits the production of reactive oxygen species (ROS), making it a valuable tool in studies of oxidative stress and related signaling pathways. Its application extends to research on inflammatory diseases and metabolic disorders where ROS play a critical role.

Cat. No.

A40166

CAS No.

127810-07-5

WAY-120744

WAY-120744 is a novel naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxide that acts as a potent modulator of biological targets relevant to chemotherapeutic strategies. This compound demonstrates significant anti-cancer activity, making it suitable for applications in cancer research and drug development. Its unique structure permits exploration of mechanisms of action in various cellular contexts, providing valuable insights into the modulation of signaling pathways.

Cat. No.

A40277

CAS No.

1693766-04-9

GSK8573

GSK8573 is an inactive control compound with a specific binding affinity to BRD9, exhibiting a Kd value of 1.04 μM. While it acts as an acetyl-lysine competitive inhibitor, GSK8573 is not active against BAZ2A/B or other bromodomain family members. This compound serves as a structurally related negative control in biological experiments, allowing researchers to validate findings in studies involving bromodomain interactions.

Cat. No.

A40475

CAS No.

2650530-02-0

SGC-BRDVIII-NC

SGC-BRDVIII-NC is a negative control compound for SMARCA2/4 and PB1 bromodomain inhibition. This compound effectively disrupts protein-ligand interactions by methylating the phenolic hydroxyl group, validating its use as a control in experimental setups. SGC-BRDVIII-NC is suitable for research applications related to adipogenesis, aiding in the understanding of the role of bromodomain inhibitors in cellular processes.

Cat. No.

A40539

CAS No.

2134675-92-4

(R)-Ziftomenib

Synonyms: (R)-KO-539

(R)-Ziftomenib is the R-enantiomer of Ziftomenib, an orally active inhibitor of the menin-MLL interaction. This compound exhibits significant antitumor activity and is primarily utilized in research focused on therapeutic strategies targeting MLL-rearranged leukemias. Its selective inhibition of menin provides a valuable tool for investigating the role of this pathway in cancer biology.

Cat. No.

A43938

CAS No.

2128714-16-7

Firsocostat (S enantiomer)

Synonyms: ND-630 (S enantiomer); GS-0976 (S enantiomer); NDI-010976 (S enantiomer)

Firsocostat (S enantiomer) is a less active form of the ACC inhibitor, Firsocostat. As an inhibitor of acetyl-CoA carboxylase, it plays a role in metabolic modulation by influencing fatty acid synthesis and oxidation. This compound is primarily utilized in research focused on metabolic disorders, obesity, and related therapeutic interventions.

Cat. No.

A48169

CAS No.

2131784-39-7

(Rac)-TBAJ-876

(Rac)-TBAJ-876 is a racemic mixture of TBAJ-876, a potent inhibitor of Mycobacterium tuberculosis. This compound serves as an analogue of the well-known anti-tuberculosis agent Bedaquiline, exhibiting promising anti-mycobacterial activity. (Rac)-TBAJ-876 is utilized in research aimed at understanding and combating tuberculosis, contributing valuable insights into therapeutic strategies against this infectious disease.

Cat. No.

A48597

CAS No.

3075275-82-7

(R)-DS86760016

(R)-DS86760016 is a potent inhibitor of leucyl-tRNA synthetase (LeuRS), specifically the R-enantiomer of the compound DS86760016. This reagent exhibits significant antimicrobial activity against multidrug-resistant Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. It is essential for research applications focused on combating antibiotic resistance and studying bacterial protein synthesis.

Cat. No.

A51870

CAS No.

256328-82-2

Desthiazolylmethyl ritonavir

Desthiazolylmethyl ritonavir is a degradation product of the HIV protease inhibitor ritonavir, formed through a base-catalyzed mechanism. This compound may be utilized in research to study the stability and degradation pathways of protease inhibitors, contributing to a deeper understanding of drug metabolism and resistance in HIV therapy. Its relevance extends to evaluating the structural integrity and efficacy of antiretroviral agents in therapeutic applications.

Cat. No.

A51892

CAS No.

827591-04-8

GSK984

GSK984 serves as an inactive control probe for GSK983, a well-characterized dihydroorotate dehydrogenase (DHODH) inhibitor known for its antiviral properties. This compound facilitates the understanding of target specificity and mechanism by providing a baseline for comparison in experimental setups. Researchers can utilize GSK984 to validate findings related to DHODH inhibition and its implications in antiviral research.

Cat. No.

A52336

CAS No.

2650846-59-4

OSM-S-106

OSM-S-106 is a pro-inhibitor targeting PfAsnRS, with its inhibition mechanism involving the enzyme-mediated formation of an Asn-OSM-S-106 adduct. This compound effectively inhibits protein translation and induces an amino acid starvation response. Demonstrating selective activity against both Plasmodium blood and liver stages, OSM-S-106 also exhibits low intrinsic clearance in human microsomes, making it a valuable tool for malaria research and studies focused on amino acid metabolism.